Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

NCT00779337 is registered in ClinicalTrials.gov with Queensland Institute of Medical Research as lead sponsor.

NCT NCT00779337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00779337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Lead sponsor
Queensland Institute of Medical Research
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
May 31, 2012
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma